Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Eric Raymond

Eric Raymond


Saint-Joseph Hospital

Prof Eric Raymond is consultant, head of medical oncology at the Paris Saint-Joseph Hospital.

Eric Raymond is board certified MD specialised in medical oncology and obtained a PhD degree in cellular and molecular biology, working on preclinical mechanisms of action and combinations of several novel anticancer drugs. He was appointed as Chef de Clinique in Paris 6 Curie University with Prof. A. de Gramont for two years before undertaking a 2-year post-doctoral fellowship with Daniel D. von Hoff at the Cancer Therapy and Research Center and Institute for Drug Development at the University of Texas in San Antonio, USA. He then undertook clinical and translational research in phase1-2 clinical studies of early drug development at the Gustave-Roussy Institute, Villejuif, France for 7 years. 

Eric Raymond was appointed as full professor of oncology at the University of Paris VII (Denis Diderot) and chair of the Medical Oncology Department at Bichat-Beaujon University Hospitals, Clichy, France in 2004. He was also appointed as full professor of medical oncology at the university of Lausanne in 2014. Over more than 10 years of experience as a chair of oncology in France and Switzerland, Prof Raymond has developed medical and research skills in patient care, oncology teaching, research, regulatory requirement, management and team building.

Eric Raymond has specialised in various areas of drug development focusing on translational laboratory research and early clinical trials focusing on drugs and therapeutics with novel mechanisms of action. He has developed a large number of academic- and industry-sponsored projects both in the lab and the clinic. Current focus is related to bridge preclinical and translational data to clinical applications to accelerate novel drug positioning both for safety and efficacy. Work is ongoing to develop tumour tissue-based biomarkers, liquid biopsy, and in-patient molecular imaging.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.